Dr Nicole Lamanna's Thoughts on the Recent FDA Approval of Acalabrutinib in CLL

[AussieNeil]

"The introduction of BTK inhibitor therapy has truly transformed the treatment landscape in chronic lymphocytic leukemia (CLL).

:

Despite (Ibrutinib's) efficacy, certain adverse events can lead to dose reductions or discontinuation of therapy in many patients with CLL receiving ibrutinib, including fatigue, arthralgias, cardiac arrythmias such as atrial fibrillation, hypertension, and increased risk of bleeding. Second-generation BTK inhibitors such as acalabrutinib and zanubrutinib were developed with the hope of similar or possibly improved efficacy and reduced toxicity compared with ibrutinib. Early phase I/II studies of acalabrutinib in CLL indeed suggested that this agent appears to have fewer adverse events than its predecessor. In November 2019, acalabrutinib gained FDA approval for the treatment of CLL or small lymphocytic lymphoma (SLL) based on results from the phase III ELEVATE-TN and ASCEND trials.

Full article clinicaloptions.com/oncolog...

Approval announcement of Acalabrutinib for CLL in Australia, Canada and USA

healthunlocked.com/cllsuppo...

List of BTKis approved and in trial

healthunlocked.com/cllsuppo...

This is an unlocked post healthunlocked.com/cllsuppo...

Neil

[MystyUK]

Thank you for the post, it's very reassuring to read as someone who has recently started Acalabrutinib. I hope you are feeling better. Oh and what a beautiful pic of a Koala 💕

[Sushibruno]

😊👏👏